
A recent study investigated GT90001, an anti-ALK-1 monoclonal antibody, combined with nivolumab for advanced hepatocellular carcinoma (HCC). The research, conducted between 2019 and 2022, involved 20 patients. In phase 1b, GT90001 7.0 mg/kg was confirmed as the recommended dose. Common severe side effects included decreased platelet count (15%), with no reported deaths due to adverse events. The treatment showed a 30% confirmed overall response rate and a disease control rate of 40%. Median progression-free survival was 2.81 months, with some patients experiencing pseudo-progression. The combination demonstrates manageable safety and promising anti-tumor activity in advanced HCC patients.
Like
Save
Share